MARKET

REGN

REGN

Regeneron Pharmaceuticals
NASDAQ
567.74
+7.98
+1.43%
After Hours: 568.00 +0.26 +0.05% 19:25 07/11 EDT
OPEN
558.39
PREV CLOSE
559.76
HIGH
568.46
LOW
551.48
VOLUME
844.64K
TURNOVER
--
52 WEEK HIGH
1,207.86
52 WEEK LOW
476.49
MARKET CAP
61.30B
P/E (TTM)
14.45
1D
5D
1M
3M
1Y
5Y
1D
Accelerated FDA Approval of Lynozyfic May Change the Case for Investing in Regeneron (REGN)
Simply Wall St · 7h ago
Regeneron Pharma Is Maintained at Neutral by UBS
Dow Jones · 18h ago
Regeneron Pharma Price Target Raised to $584.00/Share From $560.00 by UBS
Dow Jones · 18h ago
UBS Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $584
Benzinga · 18h ago
Benjamin Graham Detailed Fundamental Analysis - REGN
NASDAQ · 19h ago
SA analyst upgrades/downgrades: CVX, TLRY, LULU, REGN
Seeking Alpha · 20h ago
Regeneron Pharmaceuticals Launches Long-Term Follow-Up Study on Gene Modified T Cell Therapy
TipRanks · 21h ago
Regeneron’s Cemiplimab Study: A New Hope for Skin Cancer Treatment?
TipRanks · 21h ago
More
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Webull offers Regeneron Pharmaceuticals Inc stock information, including NASDAQ: REGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading REGN stock methods without spending real money on the virtual paper trading platform.